LIFEMAX BIOTECHNOLOGY, INC.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
1. AMB-066
2. AMB-104
2. AMB-104
Founded Year
2014
Unified Business No.
24747226
Status
Active
Number of Employees
0
Total Paid-in
Capital
17,218,050 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
AmMax was founded in 2020 by Larry Hsu, PhD in partnership with Amgen and has built a robust pipeline addressing significant unmet needs for large commercial opportunities based on its CSF1R-targeting platform.
The Company leverages its internal and external expertise in acquiring oncology assets and identifying new mechanisms or applications and developing them into first-in-class and/or best-in-class products.
AmMax's portfolio of drug candidates is led by AMB-066, a potent monoclonal antibody designed to treat patients with colorectal cancer with minimal residual disease (CRC MRD) to avoid or delay recurrence.
The Company leverages its internal and external expertise in acquiring oncology assets and identifying new mechanisms or applications and developing them into first-in-class and/or best-in-class products.
AmMax's portfolio of drug candidates is led by AMB-066, a potent monoclonal antibody designed to treat patients with colorectal cancer with minimal residual disease (CRC MRD) to avoid or delay recurrence.
